ArticleMedicine2026
Aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder (NMOSD) complicated with acute pancreatitis: A case report.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleNeuromyelitis optica spectrum disorders (NMOSD) is an autoimmune-mediated central nervous system (CNS) inflammatory demyelinating disease characterized by 6 major clinical syndromes, including myelitis, optic neuritis, area postrema syndrome, symptomatic cerebral syndrome, brainstem syndromes, and acute diencephalic clinical syndrome. PATIENT CONCERNS: A 32-year-old female, complaining of numbness in her right limb for 1 month, was diagnosed with aquaporin-4 antibody (AQP4-IgG)-positive NMOSD. She developed acute pancreatitis (AP) during disease relapse, representing a rare extra-neurological manifestation of NMOSD. DIAGNOSES: Spinal contrast-enhanced magnetic resonance imaging scan indicated hyperintense lesions on the T2-weighted sequence in the spinal cord at C2/C4 at the initial onset and extending from C2 to C6 vertebral levels at the recurrence of the disease. Serological profiling demonstrated a significant rise in AQP4-IgG titers (from 1:100 to 1:1000). During the recurrence of NMOSD, the patient manifested acute gastrointestinal symptoms, including severe epigastric pain with emesis. Laboratory tests revealed profound hyperamylasemia (amylase, 2293.8 U/L; pancreatic amylase, 1843.6 U/L). Abdominal computed tomography scan demonstrated definitive signs of AP, confirming the diagnosis.
interventionsShe received methylprednisolone and mycophenolate mofetil for NMOSD treatment. When AP occurred, she was placed on nil per os status and treated with gabexate and esomeprazole. OUTCOMES: The patient was discharged with relief of neurological dysfunction symptoms and maintained on nasojejunal tube feeding for nutritional support. Three months after discharge, clinical assessment revealed stable myelitis symptoms. There was no evidence of pancreatitis recurrence during the follow-up period. LESSONS: This case suggests that AQP4-IgG-mediated immune damage may not be confined to the CNS. There may be a possible association between NMOSD and AP in the pathophysiological mechanisms. AP may be a rare extra-CNS complication of NMOSD. Our case expands the spectrum of potential systemic complications in NMOSD, highlighting the need for increased clinical vigilance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.